Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs

Que, Zujun; Yao, Jialiang; Zhou, Zhiyi; Pan, Yu; Luo, Bin; Li, Hegen; Liu, Jiaxiang; Hong, Xu; Tian, Jie

doi:10.1016/j.jep.2021.114175

Cited by 15 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lu et al indicated that JFK causes epigenetic alteration to H3K4Me3 of the promoters of tumor-related pathways’ genes such as SUSD2 , CCND2 , BCL2A1 , and TMEM158 [ 111 ]. Que et al revealed that the application of the Chinese formula induced apoptosis of CTCs in NK cells through the Fas/FasL signaling pathway [ 112 ]; furthermore, subsequent studies showed that Jinfukang induces anoikis of CTCs by suppressing the integrin/Src axis [ 113 ], and inhibits metastasis of CTCs by suppressing the EGF pathway [ 114 ] or activating the ROS-mediated ATM/ATR-P53 pathway and causing DNA damage [ 110 ]. Moreover, Huang et al highlighted that the combination of Jin Fu Kang Decoction (JFKD) with gefitinib had a cytotoxic effect on gefitinib-resistant lung cancer cells [ 115 ].…”

Section: Detailed Results and Discussionmentioning

confidence: 99%

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives

Sulewska

Pilz

Manegold

et al. 2023

Cells

View full text Add to dashboard Cite

Epigenetic research has the potential to improve our understanding of the pathogenesis of cancer, specifically non-small-cell lung cancer, and support our efforts to personalize the management of the disease. Epigenetic alterations are expected to have relevance for early detection, diagnosis, outcome prediction, and tumor response to therapy. Additionally, epi-drugs as therapeutic modalities may lead to the recovery of genes delaying tumor growth, thus increasing survival rates, and may be effective against tumors without druggable mutations. Epigenetic changes involve DNA methylation, histone modifications, and the activity of non-coding RNAs, causing gene expression changes and their mutual interactions. This systematic review, based on 110 studies, gives a comprehensive overview of new perspectives on diagnostic (28 studies) and prognostic (25 studies) epigenetic biomarkers, as well as epigenetic treatment options (57 studies) for non-small-cell lung cancer. This paper outlines the crosstalk between epigenetic and genetic factors as well as elucidates clinical contexts including epigenetic treatments, such as dietary supplements and food additives, which serve as anti-carcinogenic compounds and regulators of cellular epigenetics and which are used to reduce toxicity. Furthermore, a future-oriented exploration of epigenetic studies in NSCLC is presented. The findings suggest that additional studies are necessary to comprehend the mechanisms of epigenetic changes and investigate biomarkers, response rates, and tailored combinations of treatments. In the future, epigenetics could have the potential to become an integral part of diagnostics, prognostics, and personalized treatment in NSCLC.

show abstract

Section: Detailed Results and Discussionmentioning

confidence: 99%

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives

Sulewska

Pilz

Manegold

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Activated NK cells express FasL and bind to Fas on the surface of tumor cells to activate apoptosis of target cells. 72 , 75 In the HCC environment, the low infiltration of NK cells will prevent the FasL on the surface of NK cells from combining with the Fas on the surface of tumor cells to induce the apoptosis of HCC. In addition, some studies have confirmed that while the infiltration of NK cells is low, HCC cells also highly express FasL, which binds to Fas on the surface of lymphocytes to induce apoptosis of lymphocytes and induce immune escape of HCC cells.…”

Section: Discussionmentioning

confidence: 99%

PVALB Was Identified as an Independent Prognostic Factor for HCC Closely Related to Immunity, and Its Absence Accelerates Tumor Progression by Regulating NK Cell Infiltration

Gong,

Zhou,

Zhu

et al. 2024

JHC

View full text Add to dashboard Cite

Purpose Hepatocellular carcinoma is the most common primary liver cancer, with poor prognosis. Complex immune microenvironment of the liver is linked to the development of HCC. PVALB is a calcium-binding protein which has been described as a cancer suppressor gene in thyroid cancer and glioma. Nevertheless, the role of PVALB in HCC is unknown. Materials and Methods We obtained data from TCGA and GSE54236 datasets. MCP-counter, WGCNA and LASSO model were applied to identify PVALB. With UALCAN, MethSurv, and other websites, we probed the expression, methylation and survival of PVALB. LinkedOmics and GSEA were adopted for functional analysis, while TIMER, TISIDB, Kaplan-Meier plotter, TIDE databases were utilized to evaluate the relevance of PVALB to the tumor immune microenvironment and predict immunotherapy efficacy. TargetScan, DIANA, LncRNASNP2 databases and relevant experiments were employed to construct ceRNA network. Finally, molecular docking and drug sensitivity of PVALB were characterized by GeneMANIA, CTD, and so on. Results PVALB was recognized as a gene associated with HCC and NK cell. Its expression was down-regulated in HCC tissue, which lead to adverse prognosis. Besides, the hypomethylation of PVALB was related to its reduced expression. Notably, PVALB was tightly linked to immune, and its reduced expression attenuated the anticancer effect of NK cells via the Fas/FasL pathway, leading to a adverse outcome. The lnc-YY1AP1-3/hsa-miR-6735-5p/PVALB axis may regulate the PVALB expression. Finally, we found immunotherapy might be a viable treatment option. Conclusion In a word, PVALB is a prognostic indicator, whose low expression facilitates HCC progression by impacting NK cell infiltration.

show abstract

“…Binding to their respective receptors leads to activation of caspase-dependent apoptosis in the target cell (Morvan and Lanier, 2016). Recently, Que et al (2021) have shown that Jinfukang can induce the expression of FasL and secretion of TNF in NK cells in vitro, which leads to induction of apoptosis through activation of the Fas/FasL signaling pathway in a CTC cell line, showing a mechanistic link between NK cells and CTCs. In vivo, this leads to increased elimination of CTCs and inhibition of CTC lung metastasis.…”

Section: Nk Cellsmentioning

confidence: 99%

Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance

et al. 2022

View full text Add to dashboard Cite

Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs

Cited by 15 publications

References 26 publications

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives

A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives

PVALB Was Identified as an Independent Prognostic Factor for HCC Closely Related to Immunity, and Its Absence Accelerates Tumor Progression by Regulating NK Cell Infiltration

Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance

Contact Info

Product

Resources

About